

Electronic Supplementary Information (ESI):

Water-soluble phosphorescent iridium(III) complexes as multicolor probes for imaging of homocysteine and cysteine in living cells

Yun Ma,^{a,c} Shujuan Liu,^{a,c} Huiran Yang,^a Yongquan Wu,^b Chengjiang Yang,^a Xiangmei Liu,^a Qiang Zhao,^{*a} Huazhou Wu,^b Jiacai Liang,^a Fuyou Li^{*b} and Wei Huang^{*a}

1. ¹H NMR, ¹³C NMR and MS (MALDI-TOF) date

[Ir(dfppy)₂cpa]⁺PF₆⁻ (Ir1'): Yield 63% ¹H NMR (400 MHz, CDCl₃, 298K): 9.32 (s, 1H), 8.88(d, 1H), 8.57 (d, 1H), 8.54 (s, 1H), 8.33 (d, 1H), 8.29 (d, 2H), 8.25 (d, 1H), 7.90-7.94 (dd, 1H), 7.74-7.81(m,3H), 7.29-7.33 (t, 2H), 6.99-7.03(t, 1H), 6.91-6.94(t, 1H), 6.59-6.66 (m, 2H), 5.76-5.79(m,2H), 4.40 (s, 2H). MS (MALDI-TOF) [m/e]: 772.2 [Ir1'-PF₆]⁺.

[Ir(t-buppy)₂cpa]⁺PF₆⁻ (Ir2'): Yield 66% ¹H NMR (400 MHz, CDCl₃, 298K): 9.12 (s, 1H), 8.82(d, 1H), 8.54 (s, 1H), 8.48 (d, 1H), 8.20 (d, 1H), 8.16 (d, 1H), 7.83-7.88 (m, 3H), 7.69-7.74 (m, 3H), 7.60-7.63(dd,2H), 7.32-7.36 (dd, 2H), 7.09-7.13(m, 2H), 6.84-6.92 (m, 2H), 6.38-6.40 (dd, 2H), 4.40 (s, 2H), 1.11 (d, 18H). MS (MALDI-TOF) [m/e]: 884.2 [Ir2'-PF₆]⁺.

[Ir(thq)₂cpa]⁺PF₆⁻ (Ir3'): Yield 58% ¹H NMR (400 MHz, CDCl₃, 298K): 9.16 (s, 1H), 8.9(d, 1H), 8.48 (s, 1H), 8.39 (d, 1H), 8.36 (d, 1H), 8.32 (d, 1H), 8.02-8.09 (dd, 2H), 7.93-7.97 (dd, 1H), 7.60 (d, 3H), 7.55 (d, 1H), 7.40-7.43(t, 3H), 7.18-7.22 (t, 2H), 6.85-6.93(m, 2H), 6.74-6.82(m, 2H), 6.36-6.39 (t, 2H), 4.39 (s, 2H). MS (MALDI-TOF) [m/e]: 884.3 [Ir3'-PF₆]⁺.

[Ir(pba)₂cpa]⁺PF₆⁻ (Ir4'): Yield 69% ¹H NMR (400 MHz, CDCl₃, 298K): 9.76 (d, 2H), 9.24(s, 1H), 8.80 (d, 1H), 8.52-8.55 (d, 2H), 8.23 (d, 1H), 8.19 (d, 1H), 8.04-8.09 (dd, 2H), 7.84-7.91 (m, 4H), 7.74-7.77 (dd, 1H), 7.58-7.61 (t, 2H), 7.43-7.46(t, 2H), 7.11-7.13 (t, 1H), 7.11-7.13 (t, 1H), 7.05-7.07 (t, 1H), 6.80-6.83 (d,2H), 4.40 (d, 2H). MS (MALDI-TOF) [m/e]: 828.2 [Ir4'-PF₆, Cl]⁺.

[Ir(dfppy)₂pto]⁺PF₆⁻ (Ir1): Yield 19% ¹H NMR (400 MHz, CDCl₃, 298K): 9.62 (d, 1H), 8.74(s, 1H), 8.59 (d, 1H), 8.31 (d, 2H), 8.24 (d, 1H), 8.14 (d, 1H), 7.91-7.94 (t, 1H), 7.75-7.78 (t, 3H), 7.28-7.30 (t,2H), 6.90-6.96 (m, 2H), 6.57-6.63(t, 2H), 5.76-5.79(t, 2H), 3.66-3.72 (dd, 6H), 1.45 (t, 9H). ¹³C NMR (100 MHz, CDCl₃, δ): 167.93, 167.87, 164.40, 150.36, 148.56, 148.36, 147.18, 143.67, 143.61, 138.09, 138.05, 131.90, 130.87, 130.78, 124.87, 124.79, 123.17, 122.78, 122.70, 119.65, 119.59, 54.73, 8.11ppm. MS (MALDI-TOF) [m/e]: 909.5 [Ir1-PF₆, Cl]⁺.


[Ir(t-buppy)₂pto]⁺PF₆⁻ (Ir2): Yield 36% ¹H NMR (400 MHz, CDCl₃, 298K): 9.61 (d, 1H), 8.73 (s, 1H), 8.60 (d, 1H), 8.15 (d, 1H), 8.08 (d, 1H), 7.84-7.90 (m, 3H),

7.67-7.74 (m, 3H), 7.61 (d, 2H), 7.30(d, 2H), 7.08 (d, 2H), 6.82-6.87(dd, 2H), 6.36-6.39 (d, 2H), 4.9 (d, 2H), 3.74-3.79 (dd, 6H), 1.48-1.51 (t, 9H), 1.09 (t, 18H). ^{13}C NMR (100 MHz, CDCl_3 , δ): 168.19, 164.05, 153.98, 150.59, 148.47, 148.33, 147.17, 140.96, 140.92, 137.90, 131.15, 128.07, 126.59, 126.52, 124.44, 124.37, 122.49, 120.11, 119.16, 55.27, 53.82, 53.45, 34.64, 31.75, 31.15, 29.38, 29.26, 8.23 ppm. MS (MALDI-TOF) [m/e]: 949.5 $[\text{Ir2-PF}_6, \text{Cl}]^+$.

[Ir(thq)₂pto]⁺PF₆⁻ (Ir3): Yield 17% ^1H NMR (400 MHz, CDCl_3 , δ): 9.74 (d, 1H), 8.8 (s, 1H), 8.66 (d, 1H), 8.23 (d, 1H), 8.17 (d, 1H), 7.87-7.91 (m, 3H), 7.78-7.80 (dd, 1H), 7.69-7.72 (m, 5H), 7.25 (d, 1H), 7.03-7.07(t, 2H), 6.89-6.95(m, 2H), 6.84-6.87 (dd, 2H), 6.34-6.37(t, 2H), 5.00 (s, 2H), 3.81-3.87 (dd, 6H), 1.5-1.53 (t, 9H). ^{13}C NMR (100 MHz, CDCl_3 , δ): 167.93, 167.87, 164.40, 150.36, 149.90, 148.56, 148.36, 147.18, 143.67, 143.61, 138.09, 138.05, 131.90, 130.87, 130.78, 126.16, 124.87, 124.79, 123.23, 123.17, 122.78, 122.70, 119.65, 119.59, 54.73, 8.11 ppm. MS (MALDI-TOF) [m/e]: 949.7 $[\text{Ir3-PF}_6, \text{Cl}]^+$.

[Ir(pba)₂pto]⁺PF₆⁻ (Ir4): Yield 37% ^1H NMR (400 MHz, CDCl_3 , 298K): 9.76 (s, 2H), 8.75 (s, 1H), 8.55 (d, 1H), 8.19 (d, 1H), 8.06-8.09 (t, 3H), 7.84-7.91 (m, 5H), 7.68-7.72 (dd, 1H), 7.58-7.60 (m, 2H), 7.42 (d, 1H), 7.38 (d, 1H), 7.03-7.07(t, 2H), 7.02-7.10(m, 2H), 6.81-6.84 (dd, 2H), 3.66-3.72 (dd, 6H), 1.46-1.49 (t, 9H). ^{13}C NMR (100 MHz, CDCl_3 , δ): 192.47, 166.08, 150.54, 149.87, 159.74, 149.93, 149.04, 148.97, 147.02, 146.88, 144.31, 138.90, 137.00, 136.98, 132.54, 132.42, 131.59, 126.59, 125.12, 121.23, 53.43, 8.00 ppm. MS (MALDI-TOF) [m/e]: 893.7 $[\text{Ir4-PF}_6, \text{Cl}]^+$.

2. Synthetic Procedure of the Complexes Ir1-Ir4



Scheme S1. Synthetic procedure of the complexes Ir1-Ir4. Reaction conditions: (i)

$\text{H}_2\text{SO}_4, \text{HNO}_3, 160^\circ\text{C}-170^\circ\text{C}, 2\text{h}$; (ii) 5% Pd/C, hydrazine hydrate, EtOH , reflux, 5h;

(iii) chloroacetyl chloride, triethylamine, R.T., overnight; (iv) $[\text{Ir}(\text{C}^{\wedge}\text{N})_2\text{Cl}_2]_2$, CH_2Cl_2 , MeOH, reflux, 4h; (v) KPF_6 , R.T., 1h; (vi) DMF, triethylamine, $110\text{ }^{\circ}\text{C}$, 3h.

3. Low-temperature (77K) normalized photoluminescence spectra




Fig. S1. Low-temperature (77K) normalized photoluminescence spectra of **Ir1-Ir4** in CH_2Cl_2 .

4. Photoluminescence spectra and luminescent photographs of Ir4 in different solvents




Fig. S2. Normalized photoluminescence spectra and luminescent photographs of **Ir4** in (a) CH_2Cl_2 , (b) EtOH, (c) HEPES.

5. Z-scan confocal luminescence image




Fig. S3. The overlap Z-scan confocal luminescence image of live KB cells incubated with 20 μM **Ir1** in PBS (pH 7.0) for 30 min at 37 $^{\circ}\text{C}$.

6. Flow cytometric results of Ir4 in KB cells.





Fig. S4. Flow cytometric results of **Ir4** in KB cells. KB cells incubated with 200 μM N-ethylmaleimide for 30 min and then further incubated with 20 μM **Ir4** for 30 min (green). KB cells incubated with 20 μM **Ir4** for 30 min (blue).

7. HOMO and LUMO Distributions of Complexes Ir1-Ir4

Table S1. HOMO and LUMO Distributions of Complexes Ir1-Ir4



8. Calculated Excited Triplet States and Character of the Transitions for the Complexes

Table S2 Calculated Excited Triplet States and Character of the Transitions for the Complexes

| | λ_{cal} , nm | E_{cal} , eV | excitation | Character |
|-----|-----------------------------|-----------------------|--|---|
| Ir1 | 550 | 2.25 | HOMO→LUMO (0.44) HOMO-2→LUMO (0.38) | ${}^3\text{ML}_\text{N} \wedge_\text{N} \text{CT} + {}^3\text{LC}_\text{C} \wedge_\text{N}$ |
| Ir2 | 691 | 1.79 | HOMO→LUMO (0.70) | ${}^3\text{ML}_\text{C} \wedge_\text{N} \text{CT} + {}^3\text{LC}_\text{C} \wedge_\text{N}$ |
| Ir3 | 725 | 1.71 | HOMO→LUMO (0.70) | ${}^3\text{ML}_\text{C} \wedge_\text{N} \text{CT} + {}^3\text{LC}_\text{C} \wedge_\text{N}$ |
| Ir4 | 559 | 2.22 | HOMO→LUMO (0.66) | ${}^3\text{ML}_\text{N} \wedge_\text{N} \text{CT} + {}^3\text{LC}_\text{C} \wedge_\text{N}$ |

9. Lipophilicity ($\log P_{\text{o/w}}$) of the complexes

Table S3. Lipophilicity ($\log P_{\text{o/w}}$) of the complexes

| complex | 1 | 2 | 3 | 4 |
|-----------------------|------|------|------|------|
| $\log P_{\text{o/w}}$ | 0.29 | 0.31 | 0.19 | 0.05 |

10. Original ^1H NMR, ^{13}C NMR and MS spectra of the final compounds

